1. Individualized Medicine Pharmacogentics
Right Dose. Right Time.
First Time.
Susan Kolyno, BA, CMA, Vantari Laboratory Representative

2. 2.2 MILLION severe adverse drug reactions per year
Why Pharmacogentics Avoidable Medical Problem 700, , , , , Heart Cancer Stroke RX Car Accidents
2.2 MILLION severe adverse drug reactions per year
PATIENTS ARE AT RISK
100,000 deaths per year
By PROPERLY PRESCRIBED MEDICATIONS
COST LEADER for Mal-Practice

3. Treatment Failures Prevalent in Disease states
“Keeping in Step” “Do No Harm”
Cancer %
Alzheimers %
Arthritis %
Diabetic %
Asthma %
Anti-depressants 38%
GENETIC differences in metabolism = Treatment Failure

4. Poly-Pharmacy Alzheimer Complications in Prescribing
Patients Taking More than 3 Medications
AT RISK - 40% are over 65
More than 75% of the population have documented genetic variations that increase their risk for ADR's.
Medicines most commonly associated with ADR's are 8X more likely to go through pathways with genetic variants.

5. Avoiding ADR's Getting Right the First Time
Pharmacogenetics is the understanding of how the genetic variation alters drug response Cytochromes (CYPs) are the metabolic factories in the liver and intestines.
Poor Metabolizers: Reach maximum levels very quickly Intermediate Metabolizers: Half the highway is shut down, a patient can still metabolize but it is very difficult. Ultra Metabolizers: Have additional pathways, these patients never reach therapeutic effect. Normal Metabolizers: Have both roads open and metabolize close to normal.

6. Changing the Pattern Will YOU make the Difference?
Interactions involve cytochromes: 2C9 CYP2D6, CYP2C19, and CYP3A Individual DNA varies in Medications and Metabolism
Impacting more patients than Common Genetic testing.
MEDICATION MANAGEMENT BASED ON PATIENT METABOLISM .
More than 100 medications have drug to gene interactions
and are identified in the FDA packet and black box labels

7. Why Vantari? Focus IS On the Patient
Vantari centers it's approach on testing & hard copy results FOR the PATIENT.
Referencing our Partner CPIC, an independent consortium and 2014 date publication for physician results & poly pharmacy recommendations.
Highly complex CLIA certified.

8. Getting Started No Cost Assistance
Complete the simple form with your Vantari representative:
SET A DATE MONTHLY - Book patients for an OFF day for screening.
Representative will assist and follow up with billing or office management.
NO OUT OF POCKET
Compliance Regulated – Request Clinical Studies, Dossiers, access to CPIC.

9. Test Results - Insurance 3-5 Days
Your screening tests and follow-up are billable.

10. Contact RIGHT DOSE. RIGHT TIME. FIRST TIME
I can provide case studies, clinical data and insurance information on pharmacogentics and the impact upon the medical profession that is NOW changing prescribing methods rapidly.
Please feel free to contact me with any questions or individualized studies geared to your practice.
YOUR VANTARI REPRESENTATIVE:
Susan Kolyno Website:
RIGHT DOSE. RIGHT TIME. FIRST TIME

11. YOUR Vantari Team Accrediations
Nick G. Arroyo -Chief Executive Officer - Nick Arroyo earned his Bachelor of Science Degree in Molecular Biosciences and Biotechnology from Arizona State University. He began his career working in research in the Department of Gene and Cellular Therapy at the Arizona Heart Institute where he helped to develop an investigational stem cell therapy for heart failure and was responsible for the cell manufacturing processes required for obtaining FDA approval for phase I clinical trial.
Sean Parrish - Chief Operating Officer - Sean Parrish is co-founder of Vantari Genetics and our Chief Operating Officer. Mr. Parrish's responsibilities encompass national commercialization of our molecular diagnostics services across the entire value chain from test inception through customer development and product distribution. Mr. Parrish has been part of the development, launch and marketing strategy for SimpleCF™, Vantari's cystic fibrosis carrier screening test. Mr. Parrish obtained a Bachelor of Science degree from the University of Arizona.
Shaun R. Opie, PhDChief Science Officer - Dr. Opie holds a PhD in Biomedical Sciences/Molecular Genetics. He led all laboratory operations for an investigator initiated Phase I clinical trial using stem cells to treat cardiac disease and helped develop a proprietary cardiovascular disease gene data set for a publicly traded genomics company. In addition to clinical trial design and management for FDA regulated investigational new drugs and devices, Dr. Opie has over 10 years of operations management directing major collaborations with industry and academic partners in molecular diagnostics research and development. He has held adjunct faculty appointments in bioengineering and has numerous publications in peer reviewed medical journals and textbooks.
Phil Lamb -Senior Advisor - Phil has a track record of successfully leading growth businesses into highly responsive, client-focused service organizations. He provides legal, financial, and strategic advice to the Vantari Genetic team. In addition to his role with Vantari Genetics, he is also a principal in Infinity Software Solutions, a leading Human Resources Information System (HRIS). Phil received his J.D. from Harvard Law.

12. Preventative Patient Care
Thank You
Right Dose. Right Time.
First Time.
Preventative Patient Care
Susan Kolyno, Account Manager, Vantari Laboratories or